JP2013519645A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519645A5
JP2013519645A5 JP2012552369A JP2012552369A JP2013519645A5 JP 2013519645 A5 JP2013519645 A5 JP 2013519645A5 JP 2012552369 A JP2012552369 A JP 2012552369A JP 2012552369 A JP2012552369 A JP 2012552369A JP 2013519645 A5 JP2013519645 A5 JP 2013519645A5
Authority
JP
Japan
Prior art keywords
methylbutyl
piperidinyl
dihydro
oxy
pentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012552369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519645A (ja
JP5922587B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051830 external-priority patent/WO2011098452A1/en
Publication of JP2013519645A publication Critical patent/JP2013519645A/ja
Publication of JP2013519645A5 publication Critical patent/JP2013519645A5/ja
Application granted granted Critical
Publication of JP5922587B2 publication Critical patent/JP5922587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012552369A 2010-02-10 2011-02-08 6−アミノ−2−{[(1s)−1−メチルブチル]オキシ}−9−[5−(1−ピペリジニル)ペンチル]−7,9−ジヒドロ−8h−プリン−8−オンマレイン酸塩 Active JP5922587B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30301010P 2010-02-10 2010-02-10
US61/303,010 2010-02-10
PCT/EP2011/051830 WO2011098452A1 (en) 2010-02-10 2011-02-08 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate

Publications (3)

Publication Number Publication Date
JP2013519645A JP2013519645A (ja) 2013-05-30
JP2013519645A5 true JP2013519645A5 (enExample) 2014-03-27
JP5922587B2 JP5922587B2 (ja) 2016-05-24

Family

ID=43836817

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012552369A Active JP5922587B2 (ja) 2010-02-10 2011-02-08 6−アミノ−2−{[(1s)−1−メチルブチル]オキシ}−9−[5−(1−ピペリジニル)ペンチル]−7,9−ジヒドロ−8h−プリン−8−オンマレイン酸塩

Country Status (23)

Country Link
US (1) US8703754B2 (enExample)
EP (1) EP2534149B1 (enExample)
JP (1) JP5922587B2 (enExample)
KR (1) KR101773541B1 (enExample)
CN (1) CN102753553B (enExample)
AU (1) AU2011214468B2 (enExample)
BR (1) BR112012018904A2 (enExample)
CA (1) CA2786973C (enExample)
DK (1) DK2534149T3 (enExample)
EA (1) EA021048B1 (enExample)
ES (1) ES2525826T3 (enExample)
HR (1) HRP20141258T1 (enExample)
IL (1) IL220845A (enExample)
ME (1) ME01926B (enExample)
MX (1) MX2012009316A (enExample)
PL (1) PL2534149T3 (enExample)
PT (1) PT2534149E (enExample)
RS (1) RS53745B1 (enExample)
SG (1) SG182471A1 (enExample)
SI (1) SI2534149T1 (enExample)
SM (1) SMT201400196B (enExample)
WO (1) WO2011098452A1 (enExample)
ZA (1) ZA201205995B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
BR112012009329A2 (pt) 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
WO2013014052A1 (en) * 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
SG11201500243WA (en) * 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
US9173872B2 (en) 2012-08-24 2015-11-03 Glaxosmithkline Llc Pyrazolopyrimidine compounds
SMT201700378T1 (it) 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
KR20150085081A (ko) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
JP6216387B2 (ja) 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 新規化合物
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
EP4218724A3 (en) * 2014-08-29 2023-08-16 Corium Pharma Solutions, Inc. Microstructure array for delivery of active agents
ES2917887T3 (es) * 2014-11-13 2022-07-12 Glaxosmithkline Biologicals Sa Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias
WO2020110584A1 (ja) * 2018-11-28 2020-06-04 株式会社島津製作所 アゾ化合物の分析方法
CN118063285A (zh) * 2022-11-14 2024-05-24 中国科学院大连化学物理研究所 煤与生物质耦合利用生产醇的方法
CN118026811A (zh) * 2022-11-14 2024-05-14 中国科学院大连化学物理研究所 二氢吡喃与醋酸为原料联产1,5-戊二醇和乙醇的方法
KR20250106231A (ko) 2023-12-29 2025-07-09 (주)셀트리온 안정한 약제학적 제제

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
KR100321649B1 (ko) 1993-03-17 2002-07-22 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
CA2310896A1 (en) 1999-07-02 2001-01-02 Japan Tobacco Inc. Hcv polymerase suitable for crystal structure analysis and method for using the enzyme
CZ20013424A3 (cs) 1999-12-27 2002-02-13 Japan Tobacco Inc. Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2003085375A2 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
TW200418848A (en) 2002-10-24 2004-10-01 Glaxo Group Ltd Compounds
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
WO2004055011A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
EP1581530A1 (en) 2002-12-13 2005-10-05 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
ES2298627T3 (es) 2002-12-13 2008-05-16 Smithkline Beecham Corporation Compuestos de ciclopropilo como antagonistas de ccr5.
WO2004054581A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
DE60322423D1 (de) 2002-12-13 2008-09-04 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
BRPI0416128B8 (pt) 2003-11-03 2021-06-22 Glaxo Group Ltd dispositivo de dispensação de fluido
CN1922174A (zh) 2004-02-20 2007-02-28 贝林格尔·英格海姆国际有限公司 病毒聚合酶抑制剂
EP1748991A1 (en) 2004-04-28 2007-02-07 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
ES2361845T3 (es) 2004-08-18 2011-06-22 Pfizer, Inc. Inhibidores de arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones y tratamientos que utilizan los mismos.
EP1799256A4 (en) 2004-08-27 2009-10-21 3M Innovative Properties Co METHOD FOR TRIGGERING AN IMMUNE RESPONSE AGAINST HIV
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
JPWO2007034881A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
JP2010519186A (ja) 2007-02-19 2010-06-03 スミスクライン ビーチャム コーポレーション 免疫調節物質としてのプリン誘導体
EP2132209B8 (en) * 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
US8777708B2 (en) 2008-06-27 2014-07-15 Microsoft Corporation Targeting control in a simulated environment
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань

Similar Documents

Publication Publication Date Title
ME01926B (me) 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat
JP2013534248A5 (enExample)
JP2021063088A5 (enExample)
JP2013542247A5 (enExample)
JP2016534063A5 (enExample)
JP2013518107A5 (enExample)
JP2012532874A5 (enExample)
JP2009507909A5 (enExample)
JP2014521735A5 (enExample)
JP2017531038A5 (enExample)
HRP20150938T1 (hr) Derivati purina namijenjeni upotrebi u lijeäśenju alergijskih, upalnih i zaraznih bolesti
JP2010270124A5 (enExample)
JP2014500861A5 (enExample)
JP2013509411A5 (enExample)
JP2015523546A5 (enExample)
JP2020507589A5 (enExample)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
BR112014001798A2 (pt) compostos de tetraciclina 9-aminometila substituídos
JP2015509075A5 (enExample)
JP2013500977A5 (enExample)
JP2011505356A5 (enExample)
JP2015508068A5 (enExample)
JP2011046708A5 (enExample)
JP2016537432A5 (enExample)
JP2010521516A5 (enExample)